Sur­face On­col­o­gy reins back its lead pro­gram af­ter track­ing low-dose tox­i­c­i­ty for CD47 drug

Sur­face On­col­o­gy’s lead drug — an an­ti-CD47 an­ti­body — has run in­to some heavy tur­bu­lence, and the Cam­bridge, MA-based biotech is buck­ling up for a rough ride.

Af­ter the mar­ket closed Tues­day the com­pa­ny $SURF put out word that SRF231’s ear­ly-stage hu­man study was be­ing cur­tailed.

Dur­ing the dose es­ca­la­tion por­tion of the phase 1, two hema­to­log­ic dose-lim­it­ing tox­i­c­i­ties (DLTs) were seen at a low­er dose (12 mg/kg) than an­tic­i­pat­ed and re­solved with­out long-term tox­i­c­i­ty. Sur­face will ex­plore ad­di­tion­al dose ad­min­is­tra­tion sched­ules but will not open ex­pan­sion co­horts in the phase 1 study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.